SciELO - Scientific Electronic Library Online

 
vol.23 número2Enteropatia por OlmesartanDoença Celíaca Refratária Tipo II: Um Caso Clínico que Ilustra os Desafios Diagnósticos e Terapêuticos índice de autoresíndice de assuntosPesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


GE-Portuguese Journal of Gastroenterology

versão impressa ISSN 2341-4545

Resumo

CARNEIRO, Liliana et al. Olmesartan-Induced Sprue Like Enteropathy. GE Port J Gastroenterol [online]. 2016, vol.23, n.2, pp.101-105. ISSN 2341-4545.  https://doi.org/10.1016/j.jpge.2015.12.003.

Chronic diarrhoea is a common clinical problem in gastroenterology practice and often it is difficult to diagnose the cause. Villous atrophy is not specific and the rarer possibility of drug-induced enteritis should always be considered. Olmesartan has recently been described as a cause of drug-induced enteropathy characterized by chronic diarrhoea and varying degrees of duodenal mucosa atrophy resembling celiac disease. We describe two cases of sprue-like enteropathy in patients treated with olmesartan for arterial hypertension several years before the onset of symptoms. Patients presented severe diarrhoea and significant weight loss, and both had histological evidence of intestinal villous atrophy. The clinical signs completely resolved after drug withdrawal. Olmesartan-induced enteropathy is a new clinical entity that must be included in the differential diagnosis of villous atrophy with negative celiac serology. The clinical and histological alterations easily and completely resolve after drug discontinuation, restoring quality of life to patients and avoiding unnecessary investigation.

Palavras-chave : Atrophy/chemically induced; Diarrhoea/chemically induced; Olmesartan; Intestinal Mucosa.

        · resumo em Português     · texto em Inglês     · Inglês ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons